Basiliximab versus antithymocyte globulin for prevention of acute renal allograft rejection

Hans Sollinger, Bruce Kaplan, Mark D. Pescovitz, Benjamin Philosophe, Alan Roza, Kenneth Brayman, Kenneth Somberg

Research output: Contribution to journalArticle

119 Citations (Scopus)

Abstract

Background. Basiliximab (Simulect), a high-affinity chimeric, monoclonal antibody directed against the alpha chain of human interleukin-2 receptor (CD25), reduces the incidence of acute renal allograft rejection when used in combination with cyclosporine (Neoral) and steroids. This study was designed to compare the safety and efficacy of basiliximab to polyclonal anti-T-cell (ATGAM) therapy for the prevention of acute rejection in de novo renal transplant recipients. Methods. This 1-year, open-label, randomized trial was conducted in recipients of cadaveric or living-related donor renal transplants. All patients received cyclosporine (Neoral), mycophenolate mofetil (Cell-Cept, MMF), and corticosteroids. Patients who were randomized to basiliximab therapy received a 20 mg i.v. bolus dose on days 0 and 4, and the majority of patients were initiated on cyclosporine within 48 hr of transplantation. Patients who were randomized to antithymocyte globulin therapy (ATGAM, ATG) received 15 mg/day i.v. within 48 hr of transplant and continued treatment for up to 14 days; ATG was stopped once therapeutic cyclosporine blood levels were achieved. The initiation of cyclosporine use was delayed in the ATG group until renal function was established (serum creatinine

Original languageEnglish (US)
Pages (from-to)1915-1919
Number of pages5
JournalTransplantation
Volume72
Issue number12
StatePublished - 2001
Externally publishedYes

Fingerprint

Antilymphocyte Serum
Cyclosporine
Allografts
Kidney
Interleukin-2 Receptor alpha Subunit
Mycophenolic Acid
Transplants
Living Donors
Therapeutics
Cell- and Tissue-Based Therapy
basiliximab
Creatinine
Adrenal Cortex Hormones
Transplantation
Steroids
Monoclonal Antibodies
T-Lymphocytes
Safety
Incidence
Serum

ASJC Scopus subject areas

  • Transplantation
  • Immunology

Cite this

Sollinger, H., Kaplan, B., Pescovitz, M. D., Philosophe, B., Roza, A., Brayman, K., & Somberg, K. (2001). Basiliximab versus antithymocyte globulin for prevention of acute renal allograft rejection. Transplantation, 72(12), 1915-1919.

Basiliximab versus antithymocyte globulin for prevention of acute renal allograft rejection. / Sollinger, Hans; Kaplan, Bruce; Pescovitz, Mark D.; Philosophe, Benjamin; Roza, Alan; Brayman, Kenneth; Somberg, Kenneth.

In: Transplantation, Vol. 72, No. 12, 2001, p. 1915-1919.

Research output: Contribution to journalArticle

Sollinger, H, Kaplan, B, Pescovitz, MD, Philosophe, B, Roza, A, Brayman, K & Somberg, K 2001, 'Basiliximab versus antithymocyte globulin for prevention of acute renal allograft rejection', Transplantation, vol. 72, no. 12, pp. 1915-1919.
Sollinger H, Kaplan B, Pescovitz MD, Philosophe B, Roza A, Brayman K et al. Basiliximab versus antithymocyte globulin for prevention of acute renal allograft rejection. Transplantation. 2001;72(12):1915-1919.
Sollinger, Hans ; Kaplan, Bruce ; Pescovitz, Mark D. ; Philosophe, Benjamin ; Roza, Alan ; Brayman, Kenneth ; Somberg, Kenneth. / Basiliximab versus antithymocyte globulin for prevention of acute renal allograft rejection. In: Transplantation. 2001 ; Vol. 72, No. 12. pp. 1915-1919.
@article{6e83a4ecdabb40f7aab817c0f6a34b02,
title = "Basiliximab versus antithymocyte globulin for prevention of acute renal allograft rejection",
abstract = "Background. Basiliximab (Simulect), a high-affinity chimeric, monoclonal antibody directed against the alpha chain of human interleukin-2 receptor (CD25), reduces the incidence of acute renal allograft rejection when used in combination with cyclosporine (Neoral) and steroids. This study was designed to compare the safety and efficacy of basiliximab to polyclonal anti-T-cell (ATGAM) therapy for the prevention of acute rejection in de novo renal transplant recipients. Methods. This 1-year, open-label, randomized trial was conducted in recipients of cadaveric or living-related donor renal transplants. All patients received cyclosporine (Neoral), mycophenolate mofetil (Cell-Cept, MMF), and corticosteroids. Patients who were randomized to basiliximab therapy received a 20 mg i.v. bolus dose on days 0 and 4, and the majority of patients were initiated on cyclosporine within 48 hr of transplantation. Patients who were randomized to antithymocyte globulin therapy (ATGAM, ATG) received 15 mg/day i.v. within 48 hr of transplant and continued treatment for up to 14 days; ATG was stopped once therapeutic cyclosporine blood levels were achieved. The initiation of cyclosporine use was delayed in the ATG group until renal function was established (serum creatinine",
author = "Hans Sollinger and Bruce Kaplan and Pescovitz, {Mark D.} and Benjamin Philosophe and Alan Roza and Kenneth Brayman and Kenneth Somberg",
year = "2001",
language = "English (US)",
volume = "72",
pages = "1915--1919",
journal = "Transplantation",
issn = "0041-1337",
publisher = "Lippincott Williams and Wilkins",
number = "12",

}

TY - JOUR

T1 - Basiliximab versus antithymocyte globulin for prevention of acute renal allograft rejection

AU - Sollinger, Hans

AU - Kaplan, Bruce

AU - Pescovitz, Mark D.

AU - Philosophe, Benjamin

AU - Roza, Alan

AU - Brayman, Kenneth

AU - Somberg, Kenneth

PY - 2001

Y1 - 2001

N2 - Background. Basiliximab (Simulect), a high-affinity chimeric, monoclonal antibody directed against the alpha chain of human interleukin-2 receptor (CD25), reduces the incidence of acute renal allograft rejection when used in combination with cyclosporine (Neoral) and steroids. This study was designed to compare the safety and efficacy of basiliximab to polyclonal anti-T-cell (ATGAM) therapy for the prevention of acute rejection in de novo renal transplant recipients. Methods. This 1-year, open-label, randomized trial was conducted in recipients of cadaveric or living-related donor renal transplants. All patients received cyclosporine (Neoral), mycophenolate mofetil (Cell-Cept, MMF), and corticosteroids. Patients who were randomized to basiliximab therapy received a 20 mg i.v. bolus dose on days 0 and 4, and the majority of patients were initiated on cyclosporine within 48 hr of transplantation. Patients who were randomized to antithymocyte globulin therapy (ATGAM, ATG) received 15 mg/day i.v. within 48 hr of transplant and continued treatment for up to 14 days; ATG was stopped once therapeutic cyclosporine blood levels were achieved. The initiation of cyclosporine use was delayed in the ATG group until renal function was established (serum creatinine

AB - Background. Basiliximab (Simulect), a high-affinity chimeric, monoclonal antibody directed against the alpha chain of human interleukin-2 receptor (CD25), reduces the incidence of acute renal allograft rejection when used in combination with cyclosporine (Neoral) and steroids. This study was designed to compare the safety and efficacy of basiliximab to polyclonal anti-T-cell (ATGAM) therapy for the prevention of acute rejection in de novo renal transplant recipients. Methods. This 1-year, open-label, randomized trial was conducted in recipients of cadaveric or living-related donor renal transplants. All patients received cyclosporine (Neoral), mycophenolate mofetil (Cell-Cept, MMF), and corticosteroids. Patients who were randomized to basiliximab therapy received a 20 mg i.v. bolus dose on days 0 and 4, and the majority of patients were initiated on cyclosporine within 48 hr of transplantation. Patients who were randomized to antithymocyte globulin therapy (ATGAM, ATG) received 15 mg/day i.v. within 48 hr of transplant and continued treatment for up to 14 days; ATG was stopped once therapeutic cyclosporine blood levels were achieved. The initiation of cyclosporine use was delayed in the ATG group until renal function was established (serum creatinine

UR - http://www.scopus.com/inward/record.url?scp=0035667590&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035667590&partnerID=8YFLogxK

M3 - Article

C2 - 11773888

AN - SCOPUS:0035667590

VL - 72

SP - 1915

EP - 1919

JO - Transplantation

JF - Transplantation

SN - 0041-1337

IS - 12

ER -